The American Medical Association’s 2025 Mid-Year Updates
The following codes were approved in 2024 and Effective in 2025 but will not appear in the CPT book until 2026. One of these was effective in January 2025 after an FDA Fast track approval.
#90593 Chikungunya virus vaccine, recombinant, for intramuscular use was effective as of January 1, 2025 . This vaccine is indicated for the prevention of Chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. The World Health Organization (WHO) published an in depth article on this virus that mimics Dengue fever and Zika Virus (Chikungunya). Chikungunya is a viral disease transmitted by infected Aedes mosquitoes, particularly A. aegypti and A. albopictus. Symptoms include fever, joint pain, headache, muscle pain, rash, and fatigue. While chikungunya is not usually fatal, it can cause severe pain and long-term joint issues.
As of May 2025, the following influenza vaccine is effective for use:
90613 Influenza virus vaccine, quadrivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 40 mcg/0.4 mL dosage, for intramuscular use
As of July 2025, the following CPT codes are active for use:
#90620 Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use
#90631 Influenza virus vaccine (IIV), H5, pandemic formulation, split virus, adjuvanted, for intramuscular use
#90382 Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use
#91323 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use
#90635 Influenza virus vaccine, H5N1, derived from cell cultures, adjuvanted, for intramuscular use
#90612 Influenza virus vaccine, trivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 31.7 mcg/0.32 mL dosage, for intramuscular use
As of July 1, 2025, forty new Category III codes will be active, however they will not be included in CPT until 2026. See the AMA website for specifics regarding CPT codes 0948T-0987T (cpt-category3-codes-short-descriptors.pdf).
The description updates (effective April 1 2025) to the Proprietary Laboratory Analyses (PLA) codes can be found at CPT® PLA Codes | American Medical Association
ELEVATE MEDICAL SOLUTIONS: YOUR TRUSTED PARTNER MEDICAL CODING
At Elevate, we’re dedicated to helping medical coders like you excel. Stay ahead of the curve by subscribing to our blog for the latest resources, industry insights, and exclusive webinars where you can earn AHIMA-approved CEUs—all for free.
Join Our Community Today!